Log In
Print
BCIQ
Print
Print this Print this
 

Biosimilar rituximab (BI 695500)

  Manage Alerts
Collapse Summary General Information
Company Boehringer Ingelheim GmbH
DescriptionRituximab biosimilar
Molecular Target CD20
Mechanism of ActionAntibody
Latest Stage of DevelopmentPhase III
IndicationRheumatoid arthritis (RA)
Partner

 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today